HIV Immunotherapy (Clinical Trial)

Enhanced T Cell Engraftment Realized with Retrovirus Vector

Published in Gene Therapy Weekly, March 2nd, 1998

Engraftment of antiviral gene-modified T cells in HIV infected patients was enhanced by retrovirus-mediated delivery.

With the advancement of gene technologies, researchers have been exploring the clinical applications of gene therapy for HIV/AIDS patients. Of the viral products of HIV that might be targeted genetically, disrupting Rev shows promise. Rev is a regulatory protein required for productive viral replication and plays an important role in the activation of virus in infected cells.

In previous research, Clive Woffendin et al. (PNAS 1996;93:2889-94) tested the ability of a mutant inhibitory form of the Rev protein (Rev M10) transduced with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1998-03-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry